{"id":"https://openalex.org/W2549237154","doi":"https://doi.org/10.1182/blood.v108.11.1854.1854","title":"Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.","display_name":"Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2549237154","doi":"https://doi.org/10.1182/blood.v108.11.1854.1854","mag":"2549237154"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.1854.1854","doi":"https://doi.org/10.1182/blood.v108.11.1854.1854","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.1854.1854","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048748466","display_name":"Lewis B. Silverman","orcid":"https://orcid.org/0009-0007-7275-7650","observed_orcids":["https://orcid.org/0009-0007-7275-7650"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lewis B. Silverman","raw_affiliation_strings":["Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102723376","display_name":"Kristen E. Stevenson","orcid":"https://orcid.org/0000-0002-0647-1431","observed_orcids":["https://orcid.org/0000-0002-0647-1431"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kristen Stevenson","raw_affiliation_strings":["Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003947352","display_name":"Donna S Neuberg","orcid":"https://orcid.org/0000-0003-2566-3145","observed_orcids":["https://orcid.org/0000-0003-2566-3145"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Donna Neuberg","raw_affiliation_strings":["Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jane O\u2019Brien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jane O\u2019Brien","raw_affiliation_strings":["Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089509810","display_name":"Jeffrey G. Supko","orcid":"https://orcid.org/0000-0002-4599-3267","observed_orcids":["https://orcid.org/0000-0002-4599-3267"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeffrey Supko","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082614208","display_name":"Stephen E. Sallan","orcid":"https://orcid.org/0000-0002-1064-8981","observed_orcids":["https://orcid.org/0000-0002-1064-8981"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen E. Sallan","raw_affiliation_strings":["Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5003947352","https://openalex.org/A5089509810","https://openalex.org/A5102723376"],"corresponding_institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.35954568,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"108","issue":"11","first_page":"1854","last_page":"1854"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pegaspargase","display_name":"pegaspargase","score":0.9259999990463257},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.8220000267028809},{"id":"https://openalex.org/keywords/childhood-acute-lymphoblastic-leukemia","display_name":"childhood acute lymphoblastic leukemia","score":0.9539999961853027},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/asparaginase-toxicity","display_name":"asparaginase toxicity","score":0.765999972820282},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.6439999938011169},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":0.925000011920929},{"id":"https://openalex.org/keywords/pancreatitis","display_name":"pancreatitis","score":0.8759999871253967},{"id":"https://openalex.org/keywords/asparagine-depletion","display_name":"asparagine depletion","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.5669999718666077}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7653565406799316},{"id":"https://openalex.org/C2778904437","wikidata":"https://www.wikidata.org/wiki/Q105296036","display_name":"Asparaginase","level":4,"score":0.7348078489303589},{"id":"https://openalex.org/C54400483","wikidata":"https://www.wikidata.org/wiki/Q1793202","display_name":"PEG ratio","level":2,"score":0.6007351875305176},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.491761714220047},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4744188189506531},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34150317311286926},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3372693955898285},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.10578644275665283},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.1854.1854","doi":"https://doi.org/10.1182/blood.v108.11.1854.1854","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.1854.1854","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.6700000166893005,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2064730869","https://openalex.org/W2316170482","https://openalex.org/W2021543137","https://openalex.org/W2332336499","https://openalex.org/W2905102299","https://openalex.org/W1559396134","https://openalex.org/W2323943295","https://openalex.org/W2356915299","https://openalex.org/W3176716215","https://openalex.org/W3112842577"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND:":[1],"E.coli":[2,34,376],"L-asparaginase":[3],"(E.coli-ASP)":[4],"is":[5,16,139,300],"an":[6],"important":[7],"component":[8],"of":[9,25,33,97,105,134,136,168,236,298,349,352,366],"multiagent":[10,108],"chemotherapy":[11],"for":[12,318],"childhood":[13],"ALL,":[14],"but":[15],"associated":[17],"with":[18,86,150,278,306,360,404],"multiple":[19],"toxicities,":[20],"including":[21,48],"allergy":[22],"in":[23,56,206,249,259,304,411,469],"25\u201330%":[24],"patients.":[26],"Pegaspargase":[27],"(PEG),":[28],"the":[29,129,137],"polyethylene":[30],"glycol":[31],"conjugate":[32],"ASP,":[35],"has":[36],"a":[37,94,106,165,324],"longer":[38],"circulating":[39],"half-life":[40],"and":[41,125,163,189,199,225,289,302,347],"potentially":[42,311],"decreased":[43],"immunogenicity.":[44],"All":[45],"ASP":[46,65,112,142,244,261,314,328,385,409,440,450,467],"preparations,":[47],"PEG,":[49,354],"have":[50,146,310],"generally":[51],"been":[52,148],"given":[53,69],"intramuscularly":[54],"(IM)":[55],"North":[57],"America,":[58],"although":[59],"limited":[60],"data":[61],"suggests":[62],"that":[63,295],"PEG":[64,99,130,170,214,299,332,369,391,395,444,457],"may":[66],"be":[67],"safely":[68],"intravenously":[70],"(IV).":[71],"METHODS:":[72],"On":[73],"DFCI":[74],"ALL":[75,89,361],"Consortium":[76],"Protocol":[77],"05-01":[78],"(open":[79],"since":[80],"May":[81,155],"2005),":[82],"all":[83],"patients":[84,251],"(pts)":[85],"newly":[87],"diagnosed":[88],"(ages":[90],"1\u201318":[91],"years)":[92],"receive":[93,363],"single":[95,166,325,388],"dose":[96,167,389],"IV":[98,169,296,331,353,368,390,394,443,456],"(2500":[100],"units/m2)":[101],"on":[102],"Day":[103],"7":[104],"32-day":[107],"induction":[109],"regimen.":[110],"Serum":[111,243,327,384,408,439,449,466],"enzyme":[113,245],"levels":[114,143,246,262,315,329,386,410,441,451,468],"(measured":[115],"by":[116,445],"validated":[117],"biochemical":[118],"assay)":[119],"are":[120,333,356],"assayed":[121],"4,":[122],"11,":[123],"18":[124,321,425,483],"25":[126,431,489],"days":[127,222,230,240,322],"after":[128,223,231,241,323,330,338,387,442],"dose.":[131,326],"Lower":[132],"limit":[133],"quantitation":[135],"assay":[138],"0.025":[140],"IU/mL.":[141],">=0.1":[144],"IU/mL":[145,412,470],"previously":[147],"correlated":[149],"asparagine":[151],"depletion.":[152],"RESULTS:":[153],"Between":[154],"2005\u2013April":[156],"2006,":[157],"66":[158],"eligible":[159],"pts":[160,273,309],"were":[161,187,195,247],"enrolled":[162],"received":[164],"during":[171,213,379],"remission":[172],"induction.":[173],"Median":[174,401,448],"age":[175,447],"was":[176,184,255],"5":[177],"years":[178,276,281],"(range":[179],"1\u201316":[180],"years),":[181],"median":[182],"WBC":[183],"11.3K/microliter,":[185],"60%":[186],"male":[188,288],"16%":[190],"had":[191],"T-cell":[192],"phenotype.":[193],"58%":[194],"considered":[196],"standard":[197],"risk":[198],"42%":[200],"high":[201],"risk.":[202],"ASP-related":[203],"toxicities":[204],"occurred":[205],"3":[207],"(4.5%)":[208],"pts.":[209,291],"Toxicities":[210],"included":[211],"hypersensitivity":[212],"infusion":[215],"(N=1),":[216],"deep":[217],"venous":[218],"thrombosis":[219],"(N=1,":[220,228],"24":[221],"PEG),":[224],"mild":[226],"pancreatitis":[227],"20":[229],"PEG).":[232,242],"1":[233],"patient":[234,446],"died":[235],"Bacillus":[237],"sepsis":[238],"(14":[239],"obtained":[248],"62":[250],"(Table":[252,283],"1).":[253],"There":[254],"no":[256],"significant":[257],"difference":[258],"serum":[260,313],"at":[263],"any":[264],"timepoint":[265],"(using":[266],"Wilcoxon":[267],"Rank":[268],"Sum":[269],"Test)":[270],"when":[271,286],"comparing":[272,287],"<":[274,459],"10":[275,460],"old":[277,282],"those":[279,336],">=10":[280,463],"2),":[284],"or":[285,374],"female":[290],"CONCLUSIONS:":[292],"We":[293],"conclude":[294],"administration":[297],"feasible":[301],"tolerable":[303],"children":[305,359],"ALL.":[307],"Most":[308],"therapeutic":[312],"(>=0.10":[316],"IU/mL)":[317],"up":[319],"to":[320,335,343,362],"similar":[334],"seen":[337],"IM":[339,375],"administration.":[340],"In":[341],"order":[342],"determine":[344],"toxicity,":[345],"efficacy":[346],"pharmacodynamics":[348],"repeated":[350],"doses":[351],"we":[355],"currently":[357],"randomizing":[358],"30":[364],"weeks":[365],"either":[367],"(given":[370,377],"every":[371],"2":[372],"weeks)":[373],"weekly)":[378],"post-induction":[380],"consolidation.":[381],"Table":[382,437],"1:":[383],"Days":[392,454],"After":[393,455],"N":[396],"Minimum":[397],"Level":[398,400,402],"Maximum":[399],"%pts":[403],"level":[405],"\u2265":[406],"0.10":[407],"4":[413,471],"45":[414],"<0.025":[415,421,433,435,490,491],"2.338":[416],"0.783":[417],"98%":[418],"11":[419,477],"52":[420,432],"1.396":[422],"0.457":[423],"94%":[424],"40":[426],"0.041":[427],"0.478":[428],"0.203":[429],"80%":[430],"0.120":[434],"2%":[436],"2:":[438],"(min,":[452],"max)":[453],"Age":[458,462],"yrs":[461,464],"p-value":[465],"0.79":[472],"(<0.025,2.34)":[473],"0.72":[474],"(0.39,1.63)":[475],"0.41":[476],"0.49":[478],"(<0.025,1.01)":[479],"0.34":[480],"(<0.025,1.40)":[481],"0.28":[482],"0.22":[484],"(0.04,0.48)":[485],"0.18":[486],"(0.05,0.40)":[487],"0.42":[488],"0.11":[492]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}